Event rates in CVOTs are usually expressed as event rate at median dosing period or events per 100 patient years. One can't just look at the BETonMACE events that have occurred during the past five months and extrapolate that event rate to the entire trial period (first patient dosed over 39 months ago; median dosing period for entire trial likely in the 22 to 24 month ballpark). We know that risk of first MACE during BETonMACE follow up period is highest during the first several months of dosing. So the event rate window over the past five months is way past this initial high risk period. We also have no official update on number of accumulated patient years. We likely are only hearing about first 3-point MACE, not recurrent MACE in patients. Only the first counts. Very likely many patients have had two or more recurrent 3-point MACE (death excluded, LOL). Long story short, we don't have enough information available to conclude too much right now about BETonMACE event rates vs. those in EXAMINE or ELIXA.

BearDownAZ